DOCSLIB.ORG

Role of Slit2 in Reducing Complications After Surgical Brain Injury Prativa Sherchan

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Role of Slit2 in Reducing Complications After Surgical Brain Injury Prativa Sherchan Loma Linda University TheScholarsRepository@LLU: Digital Archive of Research, Scholarship & Creative Works Loma Linda University Electronic Theses, Dissertations & Projects 3-2016 Role of Slit2 in Reducing Complications after Surgical Brain Injury Prativa Sherchan Follow this and additional works at: http://scholarsrepository.llu.edu/etd Part of the Medical Physiology Commons, Neurology Commons, and the Neurosciences Commons Recommended Citation Sherchan, Prativa, "Role of Slit2 in Reducing Complications after Surgical Brain Injury" (2016). Loma Linda University Electronic Theses, Dissertations & Projects. 329. http://scholarsrepository.llu.edu/etd/329 This Dissertation is brought to you for free and open access by TheScholarsRepository@LLU: Digital Archive of Research, Scholarship & Creative Works. It has been accepted for inclusion in Loma Linda University Electronic Theses, Dissertations & Projects by an authorized administrator of TheScholarsRepository@LLU: Digital Archive of Research, Scholarship & Creative Works. For more information, please contact [email protected]. LOMA LINDA UNIVERSITY School of Medicine in conjunction with the Faculty of Graduate Studies ____________________ Role of Slit2 in Reducing Complications after Surgical Brain Injury by Prativa Sherchan ____________________ A Dissertation submitted in partial satisfaction of the requirements for the degree Doctor of Philosophy in Physiology ____________________ March 2016 © 2016 Prativa Sherchan All Rights Reserved Each person whose signature appears below certifies that this dissertation in his/her opinion is adequate, in scope and quality, as a dissertation for the degree Doctor of Philosophy. , Chairperson John H. Zhang, Professor of Anesthesiology, Neurosurgery, Neurology and Physiology Daila Gridley, Professor of Radiation Medicine and Basic Sciences Richard Hartman, Professor of Psychology Andre Obenaus, Professor of Pediatrics, Associate Research Professor of Behavioral Health and Associate Professor of Basic Sciences Jiping Tang, Professor of Basic Sciences iii ACKNOWLEDGEMENTS I would like to express my heartfelt gratitude to my mentor Dr. John H. Zhang for his support, patience and guidance throughout my training. You have always inspired me to drive myself to explore the depths of scientific research. I am deeply grateful for the numerous opportunities that you have provided me with to advance not only my scientific knowledge and skills but to gain valuable leadership and managerial skills. Thank you, Dr. Zhang for your continued support. I would also like to thank my committee members Dr. Jiping Tang, Dr. Daila Gridley, Dr. Richard Hartman, and Dr. Andre Obenaus for their time, valuable advice and support. To members of Zhang Neuroscience Laboratories past and present, I would like to thank you for your friendship and the opportunities to collaborate. I am thankful for friends that I have made and the memorable times that we have spent together. To my family and friends, your love and support gives me the strength to stand up to any challenge that comes my way. I could not have done this without you. I want to thank my parents for the sacrifices that they have made so that I could have a great education and all the opportunities for success. My sister and brother, you are the rock in my life. Thank you for always being there. My little son Sid, you are the joy of my life and you make everything worth trying for. Thank you for bringing smiles to my life every day. iv CONTENT Approval Page ...................................................................................................... iii Acknowledgements .............................................................................................. iv List of Figures ....................................................................................................... ix List of Tables ........................................................................................................ x List of Abbreviations ............................................................................................. xi Abstract .............................................................................................................. xiii Chapter 1. Introduction to Surgical Brain Injury ........................................................... 1 Surgical Brain Injury ............................................................................. 2 Pathophysiology of Surgical Brain Injury .............................................. 3 Brain Edema ................................................................................... 3 Neuroinflammation .......................................................................... 3 Surgical Brain Injury Rat Model ............................................................ 4 Experimental Therapeutics for Surgical Brain Injury ............................. 8 Vascular Endothelial Growth Factors .............................................. 8 Matrix Metalloproteinases ............................................................... 9 Cyclooxygenase-2 ......................................................................... 11 Conclusion ......................................................................................... 12 References ......................................................................................... 14 2. Role of Slit2 in CNS Pathology ................................................................ 18 Introduction to Slit2-Robo ................................................................... 18 Role of Slit2 During CNS Development .............................................. 19 Role of Slit2 in CNS Disorders ........................................................... 20 Glioma ........................................................................................... 20 Traumatic and Surgical Brain Injury .............................................. 23 Cerebral Ischemia ......................................................................... 24 Intracerebral Hemorrhage ............................................................. 24 Epilepsy ........................................................................................ 25 v Role of Slit2 Dependent of Cell Types ............................................... 26 Endothelial Cells ........................................................................... 26 Pericytes ....................................................................................... 28 Regulation of Slit2-Robo in the CNS .................................................. 29 Transcription Factor Pax6 ............................................................. 29 MicroRNA 218 ............................................................................... 30 Endocannabinoids and Cannabinoid Receptors ........................... 31 Downstream Targets of Slit2-Robo Signaling in the CNS ................... 31 Small Rho-GTPase Cdc42 ............................................................ 31 Focal Adhesion Kinase ................................................................. 32 Src and Extracellular Signal-Regulated Kinase 1/2 ....................... 33 Research Question, Hypothesis and Research Aims ......................... 33 References ......................................................................................... 37 3. Recombinant Slit2 Attenuates Neuroinflammation After Surgical Brain Injury by Inhibiting Peripheral Immune Cell Infiltration via Robo1-srGAP1 Pathway in a Rat Model ................................................. 41 Abstract .............................................................................................. 42 Introduction ......................................................................................... 44 Materials and Methods ....................................................................... 46 Animals ......................................................................................... 46 Experimental Design ..................................................................... 46 Surgical Brain Injury Model ........................................................... 48 Intracerebroventricular Injection .................................................... 48 Brain Water Content Measurement ............................................... 49 Assessment of Neurological Function ........................................... 49 Enzyme Linked Immunosorbent Assay ......................................... 50 Western Blotting ............................................................................ 50 Immunohistochemistry .................................................................. 51 Cdc42 Activity Assay ..................................................................... 52 Statistical Analysis ........................................................................ 52 Results .............................................................................................. 53 Temporal Expression and Localization of Slit2 After SBI .............. 53 Temporal Expression and Localization of Robo1 After SBI ........... 55 vi Endogenous Slit2 Knockdown Worsened Outcomes After SBI ................................................................................................ 57 Recombinant Slit2 Administration Reduced Brain Edema and Improved Neurological Function 24 and 72 hours after SBI ................................................................................................ 59 Recombinant Slit2 Reduced Neuroinflammation
Load more

Recommended publications
  • The Neuronal Repellent SLIT2 Is a Target for Repression by EZH2 in Prostate Cancer
    Oncogene (2010) 29, 5370–5380 & 2010 Macmillan Publishers Limited All rights reserved 0950-9232/10 www.nature.com/onc ORIGINAL ARTICLE The neuronal repellent SLIT2 is a target for repression by EZH2 in prostate cancer JYu1,2,3,4, Q Cao2,3,JYu2,LWu1, A Dallol5,JLi2, G Chen2, C Grasso2,3, X Cao2,3, RJ Lonigro2,4, S Varambally2,3, R Mehra2,3, N Palanisamy2,3,JYWu1,8, F Latif5 and AM Chinnaiyan2,3,4,6,7 1Division of Hematology/Oncology, Department of Medicine, Northwestern University, Robert H. Lurie Comprehensive Cancer Center, Chicago, IL, USA; 2Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI, USA; 3Department of Pathology, University of Michigan, Ann Arbor, MI, USA; 4Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI, USA; 5Department of Medical and Molecular Genetics, Institute of Biomedical Research, University of Birmingham, Edgbaston, UK; 6Howard Hughes Medical Institute, University of Michigan, Ann Arbor, MI, USA; 7Department of Urology, University of Michigan, Ann Arbor, MI, USA and 8Department of Neurology, Lurie Comprehensive Cancer Center, Center for Genetic Medicine, Northwestern University, Chicago, IL, USA The neuronal repellent SLIT2 is repressed in a number of also includes SLIT1 and SLIT3. The SLIT proteins are cancer types primarily through promoter hypermethyla- evolutionary conserved and contain an N-terminal signal tion. SLIT2, however, has not been studied in prostate peptide, four leucine-rich tandem repeats, seven or nine cancer. Through genome-wide location analysis we epidermal growth factor repeats, a laminin G domain and a identified SLIT2 as a target of polycomb group (PcG) C-terminal cysteine knot (Rothberg et al., 1988).
    [Show full text]
  • Supplementary Table 1: Adhesion Genes Data Set
    Supplementary Table 1: Adhesion genes data set PROBE Entrez Gene ID Celera Gene ID Gene_Symbol Gene_Name 160832 1 hCG201364.3 A1BG alpha-1-B glycoprotein 223658 1 hCG201364.3 A1BG alpha-1-B glycoprotein 212988 102 hCG40040.3 ADAM10 ADAM metallopeptidase domain 10 133411 4185 hCG28232.2 ADAM11 ADAM metallopeptidase domain 11 110695 8038 hCG40937.4 ADAM12 ADAM metallopeptidase domain 12 (meltrin alpha) 195222 8038 hCG40937.4 ADAM12 ADAM metallopeptidase domain 12 (meltrin alpha) 165344 8751 hCG20021.3 ADAM15 ADAM metallopeptidase domain 15 (metargidin) 189065 6868 null ADAM17 ADAM metallopeptidase domain 17 (tumor necrosis factor, alpha, converting enzyme) 108119 8728 hCG15398.4 ADAM19 ADAM metallopeptidase domain 19 (meltrin beta) 117763 8748 hCG20675.3 ADAM20 ADAM metallopeptidase domain 20 126448 8747 hCG1785634.2 ADAM21 ADAM metallopeptidase domain 21 208981 8747 hCG1785634.2|hCG2042897 ADAM21 ADAM metallopeptidase domain 21 180903 53616 hCG17212.4 ADAM22 ADAM metallopeptidase domain 22 177272 8745 hCG1811623.1 ADAM23 ADAM metallopeptidase domain 23 102384 10863 hCG1818505.1 ADAM28 ADAM metallopeptidase domain 28 119968 11086 hCG1786734.2 ADAM29 ADAM metallopeptidase domain 29 205542 11085 hCG1997196.1 ADAM30 ADAM metallopeptidase domain 30 148417 80332 hCG39255.4 ADAM33 ADAM metallopeptidase domain 33 140492 8756 hCG1789002.2 ADAM7 ADAM metallopeptidase domain 7 122603 101 hCG1816947.1 ADAM8 ADAM metallopeptidase domain 8 183965 8754 hCG1996391 ADAM9 ADAM metallopeptidase domain 9 (meltrin gamma) 129974 27299 hCG15447.3 ADAMDEC1 ADAM-like,
    [Show full text]
  • Dynamic Landscape of Chromatin Accessibility and Transcriptomic
    www.nature.com/scientificreports OPEN Dynamic landscape of chromatin accessibility and transcriptomic changes during diferentiation of human embryonic stem cells into dopaminergic neurons César Meléndez‑Ramírez1,2,6, Raquel Cuevas‑Diaz Duran3,6*, Tonatiuh Barrios‑García3, Mayela Giacoman‑Lozano3, Adolfo López‑Ornelas1,2,4, Jessica Herrera‑Gamboa3, Enrique Estudillo2, Ernesto Soto‑Reyes5, Iván Velasco1,2* & Víctor Treviño3* Chromatin architecture infuences transcription by modulating the physical access of regulatory factors to DNA, playing fundamental roles in cell identity. Studies on dopaminergic diferentiation have identifed coding genes, but the relationship with non‑coding genes or chromatin accessibility remains elusive. Using RNA‑Seq and ATAC‑Seq we profled diferentially expressed transcripts and open chromatin regions during early dopaminergic neuron diferentiation. Hierarchical clustering of diferentially expressed genes, resulted in 6 groups with unique characteristics. Surprisingly, the abundance of long non‑coding RNAs (lncRNAs) was high in the most downregulated transcripts, and depicted positive correlations with target mRNAs. We observed that open chromatin regions decrease upon diferentiation. Enrichment analyses of accessibility depict an association between open chromatin regions and specifc functional pathways and gene‑sets. A bioinformatic search for motifs allowed us to identify transcription factors and structural nuclear proteins that potentially regulate dopaminergic diferentiation. Interestingly, we also found changes in protein and mRNA abundance of the CCCTC‑binding factor, CTCF, which participates in genome organization and gene expression. Furthermore, assays demonstrated co‑localization of CTCF with Polycomb‑repressed chromatin marked by H3K27me3 in pluripotent cells, progressively decreasing in neural precursor cells and diferentiated neurons. Our work provides a unique resource of transcription factors and regulatory elements, potentially involved in the acquisition of human dopaminergic neuron cell identity.
    [Show full text]
  • Slit Proteins: Molecular Guidance Cues for Cells Ranging from Neurons to Leukocytes Kit Wong, Hwan Tae Park*, Jane Y Wu* and Yi Rao†
    583 Slit proteins: molecular guidance cues for cells ranging from neurons to leukocytes Kit Wong, Hwan Tae Park*, Jane Y Wu* and Yi Rao† Recent studies of molecular guidance cues including the Slit midline glial cells was thought to be abnormal [2,3]. family of secreted proteins have provided new insights into the Projection of the commissural axons was also abnormal: mechanisms of cell migration. Initially discovered in the nervous instead of crossing the midline once before projecting system, Slit functions through its receptor, Roundabout, and an longitudinally, the commissural axons from two sides of the intracellular signal transduction pathway that includes the nerve cord are fused at the midline in slit mutants [2,3]. Abelson kinase, the Enabled protein, GTPase activating proteins Because the midline glial cells are known to be important and the Rho family of small GTPases. Interestingly, Slit also in axon guidance, the commissural axon phenotype in slit appears to use Roundabout to control leukocyte chemotaxis, mutants was initially thought to be secondary to the cell- which occurs in contexts different from neuronal migration, differentiation phenotype [3]. suggesting a fundamental conservation of mechanisms guiding the migration of distinct types of somatic cells. In early 1999, results from three groups demonstrated independently that Slit functioned as an extracellular cue Addresses to guide axon pathfinding [4–6], to promote axon branching Department of Anatomy and Neurobiology, and *Departments of [7], and to control neuronal migration [8]. The functional Pediatrics and Molecular Biology and Pharmacology, Box 8108, roles of Slit in axon guidance and neuronal migration were Washington University School of Medicine, 660 S Euclid Avenue St Louis, soon supported by other studies in Drosophila [9] and in Missouri 63110, USA *e-mail: [email protected] vertebrates [10–14].
    [Show full text]
  • Mouse SLIT2 ELISA Kit (ARG82522)
    Product datasheet [email protected] ARG82522 Package: 96 wells Mouse SLIT2 ELISA Kit Store at: 4°C Component Cat. No. Component Name Package Temp ARG82522-001 Antibody-coated 8 X 12 strips 4°C. Unused strips microplate should be sealed tightly in the air-tight pouch. ARG82522-002 Standard 2 X 10 ng/vial 4°C ARG82522-003 Standard/Sample 30 ml (Ready to use) 4°C diluent ARG82522-004 Antibody conjugate 1 vial (100 µl) 4°C concentrate (100X) ARG82522-005 Antibody diluent 12 ml (Ready to use) 4°C buffer ARG82522-006 HRP-Streptavidin 1 vial (100 µl) 4°C concentrate (100X) ARG82522-007 HRP-Streptavidin 12 ml (Ready to use) 4°C diluent buffer ARG82522-008 25X Wash buffer 20 ml 4°C ARG82522-009 TMB substrate 10 ml (Ready to use) 4°C (Protect from light) ARG82522-010 STOP solution 10 ml (Ready to use) 4°C ARG82522-011 Plate sealer 4 strips Room temperature Summary Product Description ARG82522 Mouse SLIT2 ELISA Kit is an Enzyme Immunoassay kit for the quantification of Mouse SLIT2 in serum, plasma (EDTA, heparin) and cell culture supernatants. Tested Reactivity Ms Tested Application ELISA Target Name SLIT2 Conjugation HRP Conjugation Note Substrate: TMB and read at 450 nm. Sensitivity 78 pg/ml Sample Type Serum, plasma (EDTA, heparin) and cell culture supernatants. Standard Range 156 - 10000 pg/ml Sample Volume 100 µl Precision Intra-Assay CV: 5.3% Inter-Assay CV: 6.9% www.arigobio.com 1/3 Alternate Names Slit-2; Slit homolog 2 protein; SLIL3 Application Instructions Assay Time ~ 5 hours Properties Form 96 well Storage instruction Store the kit at 2-8°C.
    [Show full text]
  • SLIT2/ROBO Signaling in Tumor-Associated Microglia/Macrophages Drives Glioblastoma Immunosuppression and Vascular Dysmorphia
    SLIT2/ROBO signaling in tumor-associated microglia/macrophages drives glioblastoma immunosuppression and vascular dysmorphia Luiz H. Geraldo, … , Anne Eichmann, Thomas Mathivet J Clin Invest. 2021. https://doi.org/10.1172/JCI141083. Research In-Press Preview Oncology Vascular biology Graphical abstract Find the latest version: https://jci.me/141083/pdf 1 SLIT2/ROBO signaling in tumor-associated microglia/macrophages drives 2 glioblastoma immunosuppression and vascular dysmorphia 3 Luiz Henrique Geraldo1,2, Yunling Xu1, Laurent Jacob1, Laurence Pibouin Fragner1, 4 Rohit Rao3, Nawal Maissa1, Maïté Verreault4, Nolwenn Lemaire4, Camille Knosp1, 5 Corinne Lesaffre1, Thomas Daubon5,6, Joost DeJaegher7,8, Lien Solie7,8, Justine 6 Rudewicz5,6, Thomas Viel1, Bertrand Tavitian1, Steven De Vleeschouwer7,8, Marc 7 Sanson4,9, Andreas Bikfalvi5,6, Ahmed Idbaih4, Q. Richard Lu3, Flavia Regina Souza 8 Lima2, Jean-Leon Thomas4.10, Anne Eichmann1,11,12,*,# and Thomas Mathivet1,*,#. 9 10 1 Université de Paris, PARCC, INSERM, F-75015 Paris, France. 11 2 Biomedical Sciences Institute, Federal University of Rio de Janeiro, Brazil. 12 3 Brain Tumor Center, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH 13 4 Sorbonne Université, Inserm U1127, CNRS UMR 7225, Institut du Cerveau, ICM, AP- 14 HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Service de Neurologie 15 2-Mazarin, F-75013, Paris, France. 16 5 Inserm U1029, 6 Université de Bordeaux, F-33170 Pessac, France. 17 7 Department of Neurosciences, 8 Department of Neurosurgery, UZ
    [Show full text]
  • Changes in SLIT2 Expression Are Associated with the Migration of Human Ovarian Clear Cell Carcinoma Cells
    ONCOLOGY LETTERS 22: 551, 2021 Changes in SLIT2 expression are associated with the migration of human ovarian clear cell carcinoma cells CUEI‑JYUAN LIN1*, WAY‑REN HUANG2*, CHIA‑ZHEN WU3 and RUO‑CHIA TSENG3 1Department of Laboratory Medicine, Keelung Chang Gung Memorial Hospital, Keelung 20401; 2GLORIA Operation Center, National Tsing Hua University, Hsinchu 30013; 3Department of Molecular Biology and Human Genetics, Tzu Chi University, Hualien 97004, Taiwan, R.O.C. Received January 8, 2021; Accepted May 5, 2021 DOI: 10.3892/ol.2021.12812 Abstract. Ovarian clear cell carcinoma (OCCC) is characterized rate of ~9% in Taiwan and various other areas of the world (1,2). by a poor survival of patients, which is mainly due to metastasis EOC has several subtypes with different origins, multiple and treatment failure. Slit guidance ligand 2 (SLIT2), a secreted molecular characteristics and a range of outcomes (3). EOC protein, has been reported to modulate the migration of neural consists of five histological subtypes, namely serous, mucinous, cells and human cancer cells. However, the effect of changes in clear cell, endometrioid and transitional cell/Brenner tumor SLIT2 expression on the regulation of cell migration in OCCC subtypes (4). Ovarian clear cell carcinoma (OCCC) is a distinct remains unknown. The present study examined alterations in type of ovarian cancer, and is associated with both a poor SLIT2 expression using OCCC cell models, including low‑ and survival and resistance to platinum‑based chemotherapy (3). high‑mobility SKOV3 cells, as well as OCCC tissues. DNA OCCC is the second most common EOC subtype in Taiwan methylation analysis suggested that promoter hypermethylation and Japan (2), whereas it ranks fourth in North America (5).
    [Show full text]
  • Supplementary Information – Postema Et Al., the Genetics of Situs Inversus Totalis Without Primary Ciliary Dyskinesia
    1 Supplementary information – Postema et al., The genetics of situs inversus totalis without primary ciliary dyskinesia Table of Contents: Supplementary Methods 2 Supplementary Results 5 Supplementary References 6 Supplementary Tables and Figures Table S1. Subject characteristics 9 Table S2. Inbreeding coefficients per subject 10 Figure S1. Multidimensional scaling to capture overall genomic diversity 11 among the 30 study samples Table S3. Significantly enriched gene-sets under a recessive mutation model 12 Table S4. Broader list of candidate genes, and the sources that led to their 13 inclusion Table S5. Potential recessive and X-linked mutations in the unsolved cases 15 Table S6. Potential mutations in the unsolved cases, dominant model 22 2 1.0 Supplementary Methods 1.1 Participants Fifteen people with radiologically documented SIT, including nine without PCD and six with Kartagener syndrome, and 15 healthy controls matched for age, sex, education and handedness, were recruited from Ghent University Hospital and Middelheim Hospital Antwerp. Details about the recruitment and selection procedure have been described elsewhere (1). Briefly, among the 15 people with radiologically documented SIT, those who had symptoms reminiscent of PCD, or who were formally diagnosed with PCD according to their medical record, were categorized as having Kartagener syndrome. Those who had no reported symptoms or formal diagnosis of PCD were assigned to the non-PCD SIT group. Handedness was assessed using the Edinburgh Handedness Inventory (EHI) (2). Tables 1 and S1 give overviews of the participants and their characteristics. Note that one non-PCD SIT subject reported being forced to switch from left- to right-handedness in childhood, in which case five out of nine of the non-PCD SIT cases are naturally left-handed (Table 1, Table S1).
    [Show full text]
  • SLIT2, a Human Homologue of the Drosophila Slit2 Gene, Has Tumor Suppressor Activity and Is Frequently Inactivated in Lung and Breast Cancers1
    [CANCER RESEARCH 62, 5874–5880, October 15, 2002] SLIT2, a Human Homologue of the Drosophila Slit2 Gene, Has Tumor Suppressor Activity and Is Frequently Inactivated in Lung and Breast Cancers1 Ashraf Dallol, Nancy Fernandes Da Silva, Paolo Viacava, John D. Minna, Ivan Bieche, Eamonn R. Maher, and Farida Latif2 Section of Medical and Molecular Genetics, Division of Reproductive and Child Health, University of Birmingham, Birmingham B15 2TT, United Kingdom [A. D., N. F. D. S., E. R. M., F. L.]; CRC Renal Molecular Oncology Research Group, University of Birmingham, Birmingham B15 2TG, United Kingdom [N. F. D. S., E. R. M., F. L.]; Department of Oncology, Division of Pathology, University of Pisa, Pisa, Italy [P. V.]; Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center, Dallas, Texas 75390 [J. D. M.]; and Laboratoire d’Oncoge´ne´tique-INSERM E0017, Centre Rene´Huguenin, F-92210 St-Cloud, France [I. B.] ABSTRACT knot (Fig. 1; Ref. 4). These motifs are also found in other proteins and have been implicated in mediating protein-protein and ECM-protein Slit2 plays a vital role in axon guidance by signaling through Robo interactions. The SLIT2 protein can be present in three forms. The receptors. Recent evidence suggests that Slit2 protein may function in full-length protein (M ϳ200,000) is proteolytically cleaved into an other settings because human and Xenopus Slit2 has been shown to inhibit r leukocyte chemotaxis. SLIT2 protein is a putative ligand for the ROBO NH2-terminal fragment and a smaller COOH-terminal fragment. It is receptors. We recently demonstrated that ROBO1 is inactivated by pro- thought that different axons have specific responses to particular moter region hypermethylation in <20% of human cancers; furthermore, SLIT2 fragments (5).
    [Show full text]
  • Transcriptional Regulation of SLIT2 Expression in Pancreatic Cancer Cell Lines Brenna A. Rheinheimer1+, Lukas Vrba2, Bernard
    bioRxiv preprint doi: https://doi.org/10.1101/2020.09.29.319129; this version posted October 1, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Transcriptional regulation of SLIT2 expression in pancreatic cancer cell lines Brenna A. Rheinheimer1+, Lukas Vrba2, Bernard W Futscher2,3, and Ronald L Heimark2,4 1Department of Nutritional Sciences, University of Arizona, Tucson, AZ 2Arizona Cancer Center, University of Arizona, Tucson, AZ 3Department of Pharmacology and Toxicology, University of Arizona, Tucson, AZ 4Department of Surgery, University of Arizona, Tucson, AZ +Corresponding Author: Brenna A Rheinheimer The University of Arizona 1177 N 4th St Room 438 PO Box 210038 Tucson, AZ 85721 Phone: (520) 626-2223 [email protected] Abstract Background: SLIT2 has been shown to serve as a tumor suppressor in breast, lung, colon, and liver cancers. Additionally, expression of SLIT2 has been shown to be epigenetically regulated in prostate cancer. Therefore, we sought to determine transcriptional regulation of SLIT2 in pancreatic ductal adenocarcinoma. bioRxiv preprint doi: https://doi.org/10.1101/2020.09.29.319129; this version posted October 1, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Methods: RNA expression of SLIT2, SLIT3, and ROBO1 was examined in a panel of pancreatic ductal adenocarcinoma cell lines while protein expression of ROBO1 and SLIT2 was examined in tumor tissue. Methylation of the SLIT2 promoter was determined using Sequenom while histone modifications were queried by chromatin immunoprecipitation.
    [Show full text]
  • Specific Expression and Methylation of SLIT1, SLIT2, SLIT3, and Mir‑218
    INTERNATIONAL JOURNAL OF ONCOLOGY 48: 2497-2507, 2016 Specific expression and methylation ofSLIT1 , SLIT2, SLIT3, and miR‑218 in gastric cancer subtypes MIRANG KIM1,2, JONG-HWAN KIM1,2, SU-JIN BAEK1,2, SEON-YOUNG KIM1,2 and YONG SUNG KIM1,2 1Genome Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB); 2Department of Functional Genomics, University of Science and Technology, Daejeon 34141, Republic of Korea Received December 20, 2015; Accepted January 27, 2016 DOI: 10.3892/ijo.2016.3473 Abstract. SLIT has been suggested as a key regulator of microsatellite instability (MSI), genomically stable (GS), and cancer development and a promising therapeutic target for chromosomal instability (CIN) (2). Nearly 9% of gastric cancer treatment. Herein, we analyzed expression and meth- cancer is EBV-positive (3), for which methylation of tumor ylation of SLIT1/SLIT2/SLIT3 in 11 gastric cancer cell lines, suppressor genes is a key abnormality (4). MSI is a common 96 paired gastric tumors and adjacent normal gastric tissues, feature of gastric cancers that occurs in 15-30% of cases (5). and 250 gastric cancers provided by The Cancer Genome DNA mismatch repair deficiency such as methylation of the Atlas. Methylation of SLIT1/SLIT2/SLIT3 was found both in MLH1 promoter increases the frequency of mutations across early gastric cancers, and in advanced gastric cancers. Even the genome, creating MSI (5). Not only MLH1 but also many normal gastric tissue showed increased methylation of SLIT1 other tumor suppressor genes are frequently hypermethylated and SLIT3 that correlated with patient age. Furthermore, in MSI-positive gastric cancer (6).
    [Show full text]
  • Structural Insights Into the Slit-Robo Complex
    Structural insights into the Slit-Robo complex Cecile Morlot*, Nicole M. Thielens†, Raimond B. G. Ravelli*, Wieger Hemrika‡, Roland A. Romijn‡, Piet Gros§, Stephen Cusack*, and Andrew A. McCarthy*¶ *European Molecular Biology Laboratory, 6 Rue Jules Horowitz, BP 181, 38042 Grenoble, France; †Laboratoire d’Enzymologie Moleculaire, Institut de Biologie Structurale J. P. Ebel, 38027 Grenoble Cedex 1, France; and ‡ABC Expression Center and §Department of Crystal and Structural Chemistry, Bijvoet Center for Biomolecular Research, Utrecht University, Padualaan 8, 3584 CH Utrecht, The Netherlands Edited by Corey S. Goodman, Renovis, South San Francisco, CA, and approved August 7, 2007 (received for review June 6, 2007) Slits are large multidomain leucine-rich repeat (LRR)-containing heterophilic interactions with Robo1. This raises the possibility proteins that provide crucial guidance cues in neuronal and vas- that Robo3 may, in fact, sequester Robo1 into an inactive cular development. More recently, Slits have been implicated in receptor complex on the developing axon to allow midline heart morphogenesis, angiogenesis, and tumor metastasis. Slits crossing (15). are ligands for the Robo (Roundabout) receptors, which belong to Slit proteins contain a unique N-terminal tandem of four the Ig superfamily of transmembrane signaling molecules. The leucine-rich repeat (LRR) domains (D1–D4) followed by seven Slit-Robo interaction is mediated by the second LRR domain of Slit to nine EGF-like domains, a laminin G domain and a C-terminal and the two N-terminal Ig domains of Robo, but the molecular cysteine-rich module (16). Proteolytic cleavage within the EGF details of this interaction and how it induces signaling remain region releases the active N-terminal fragment (17).
    [Show full text]